Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients

Summary

This is a phase II, mono institutional, non comparative study, evaluating adjuvant capecitabine in patients affected by KRAS mutated Pseudomyxoma peritonei treated with cytoreductive surgery and HIPEC. Patient will be treated with 8 cycles of the study regimen that include: Capecitabine 1250 mg/m2 PO BID day 1-14 q21 days

Timeline

Start

2018-12-03

Primary completion

2023-12

Completion

2023-12

Drugs

Indications